Landmark Trial to Link Reduction in Cardiovascular Risk With Treatment of Anemia in Diabetics With Chronic Kidney Disease
Apr 11, 2005 (BUSINESS WIRE) -- Most people with chronic kidney disease die from
cardiovascular problems before ever receiving dialysis or a
transplant. Now there's a new clinical trial called TREAT -- Trial To
Reduce Cardiovascular Events with Aranesp Therapy. The goal of the
trial is to determine if treating anemia will reduce cardiovascular
events in people with chronic kidney disease and Type 2 diabetes.
Radio News Feature
You can reach the story directly by going to
This multimedia news story is for free and unrestricted use on
your news information site (and for print or broadcast too). Visit
http://www.newstream.com to download video, audio, text, graphics and
If you have any questions about the story, or about Newstream.com,
please write to us at email@example.com.
SOURCE: Newstream and Amgen
Newstream, New York